Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor protein p53 binding protein 2 (TP53BP2 (also known as ASPP2))
- Target
- TP53BP2 (also known as ASPP2)
- Molecular classification
- Apoptosis regulator, Scaffolding protein, p53-interacting protein, SH3 domain-containing protein, Ankyrin repeat-containing protein, Tumor suppressor
01
Overview
Tumor protein p53 binding protein 2 (TP53BP2), also known as apoptosis-stimulating of p53 protein 2 (ASPP2), is a multifunctional tumor suppressor and apoptosis regulator encoded by the TP53BP2 gene. It belongs to the ASPP family and is characterized by containing four ankyrin repeats and an SH3 domain, facilitating multiple protein-protein interactions. TP53BP2 directly binds the tumor suppressor p53 and its family members, enhancing their ability to induce apoptosis by upregulating pro-apoptotic gene transcription. It localizes to the perinuclear region and modulates cell fate decisions notably in response to cellular stress. Its biological relevance is highlighted in a range of human cancers, where loss or inactivation may contribute to tumor development and progression.
- Other names
- ASPP253BP2P53BP2BBPPPP1R13ABcl2-binding protein
02
Mechanism of action
Enhances p53-mediated transactivation of pro-apoptotic genes, interacts with p53 to promote apoptosis, blocks mutant p53 binding
03
Biological functions
Apoptosis regulationCell growth controlp53 pathway regulationTranscriptional coactivationCellular stress response
04
Disease associations
Cancer (tumor suppression, particularly in breast, liver, cervical cancer, and B-cell lymphoma)Potential roles in other cancer subtypes
05
Safety considerations
No established drug safety dataconceptual concern is that targeting a tumor suppressor pathway could affect normal cell apoptotic regulation and lead to toxicity in non-cancerous tissues
06
Interacting drugs
None with direct clinical approval as of now (modulation could be under research; no direct drug hits identified in currently available structured databases)
07
Biomarkers
Expression level and/or mutation of TP53BP2 in tumors as an indicator of p53 pathway statuscancer prognosis
Beyond the preview
Go deeper on Tumor protein p53 binding protein 2 (TP53BP2 (also known as ASPP2)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor protein p53 binding protein 2 (TP53BP2 (also known as ASPP2)).